MTM(SH:688029) Sou Hu Cai Jing·2025-05-26 11:52Group 1 - The core viewpoint of the articles highlights the financial performance and market position of Nanwei Medical, indicating a decline in stock price and a relatively low PE ratio compared to the industry average [1][2] - As of May 26, Nanwei Medical's closing stock price was 65.37 yuan, down 1.60%, with a rolling PE ratio of 21.52 times and a total market capitalization of 12.28 billion yuan [1] - The average PE ratio for the medical device industry is 48.92 times, with a median of 35.68 times, placing Nanwei Medical at the 49th position in the industry ranking [1][2] Group 2 - As of March 31, 2025, Nanwei Medical had 13,313 shareholders, an increase of 639 from the previous count, with an average holding value of 352,800 yuan and an average holding quantity of 27,600 shares [1] - The company's main business involves the research, development, manufacturing, and sales of minimally invasive medical devices, including biopsy, hemostasis, closure, EMR/ESD, dilation, ERCP, EUS/EBUS products, ablation devices, disposable biliary imaging systems, and bronchoscopes [1] - In the first quarter of 2025, Nanwei Medical reported a revenue of 699 million yuan, a year-on-year increase of 12.75%, and a net profit of 161 million yuan, also reflecting a year-on-year increase of 12.18%, with a gross profit margin of 65.69% [1]